<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>22 Acute leukaemia</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
    <style>
        .image-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 1rem;
            margin-top: 1.5rem;
        }
        .image-grid figure {
            margin: 0;
        }
    </style>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-21-myelodysplasia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 55%;"></div>
                        </div>
                       <span class="progress-text">Lecture 22 of 40</span>
                    </div>
                    <a href="haematology-23-chronic-lymphocytic-leukaemia.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">22 Acute leukaemia</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="intro" class="content-section" aria-labelledby="section-heading-1">
                    <div class="content-card">
                        <p>Acute leukaemia is a malignant disorder in which haemopoietic blast cells constitute &gt;30% of bone marrow cells. The primitive cells usually also accumulate in the blood, infiltrate other tissues and cause bone marrow failure.</p>
                    </div>
                </section>

                <section id="classification" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Classification</span>
                    </h2>
                    <div class="content-card">
                        <p>There are two main groups: acute lymphoblastic (ALL); and acute myeloid (myeloblastic) leukaemia (AML). Rare cases are undifferentiated or mixed. Subclassification of ALL or AML depends on morphological, immunological, cytochemical and cytogenetic criteria (Tables 22.1-22.3).</p>
                    </div>
                </section>

                <section id="aetiology-pathogenesis" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Aetiology and pathogenesis</span>
                    </h2>
                    <div class="content-card">
                        <p>The malignant cells typically show a chromosome translocation or other DNA mutation affecting oncogenes and anti-oncogenes (see Chapter 19). AML may follow previous myeloproliferative or myelodysplastic diseases. In childhood B lineage (common) ALL there is evidence that the first event, a chromosomal translocation, may occur in utero and subsequent events (? infection) precipitate the onset of ALL.</p>
                    </div>
                </section>

                <section id="incidence" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                        <span class="heading-text">Incidence</span>
                    </h2>
                    <div class="content-card">
                        <p>Approximately 1000 new cases (20-25/million population) each of AML and ALL per year in the UK. ALL is the most common malignancy in childhood (peak age 4 years) but also occurs in adults. AML occurs at all ages but is rarer than ALL in childhood, being most common in the elderly.</p>
                    </div>
                </section>

                <section id="clinical-features" class="content-section" aria-labelledby="section-heading-5">
                    <h2 id="section-heading-5" class="section-heading">
                        <span class="heading-text">Clinical features</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Short (&lt;3-month) history of symptoms due to bone marrow failure (e.g. anaemia, abnormal bruising/bleeding or infection). Disseminated intravascular coagulation (DIC) with bleeding is particularly common in AML M3.</li>
                            <li>Increased cellular catabolism may cause sweating, fever and general malaise.</li>
                            <li>Lymphadenopathy and hepatosplenomegaly are frequent, especially in ALL.</li>
                            <li>Tissue infiltration, e.g. of meninges, testes (more common in ALL), skin, bones, gums with hypertrophy (AML M5 or M4) may cause clinical symptoms or signs.</li>
                        </ul>
                    </div>
                </section>

                <section id="laboratory-features" class="content-section" aria-labelledby="section-heading-6">
                    <h2 id="section-heading-6" class="section-heading">
                        <span class="heading-text">Laboratory features</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Anaemia, thrombocytopenia and often neutropenia.</li>
                            <li>Leucocytosis caused by blast cells in the blood usually occurs. Leucopenia is less frequent.</li>
                            <li>The bone marrow shows infiltration by blast cells (&gt;30% and often 80-90% of marrow cells).</li>
                            <li>Coagulation may be abnormal and DIC can occur, especially with AML M3.</li>
                            <li>Serum uric acid, lactate dehydrogenase (LDH) may be raised.</li>
                            <li>Morphological analysis (Figs 22.1-22.12, Table 22.1) usually reveals cytoplasmic granules or Auer rods (condensations of granules) in AML. Cytochemical stains are helpful—AML blasts have granules positive by Sudan black, myeloperoxidase and chloroacetate esterase, while monoblasts are positive for non-specific and butyrate esterase. B-lineage lymphoblasts show blocks of positive material with periodic acid-Schiff (PAS) stain, and in T-lineage ALL with acid phosphatase.</li>
                            <li>Immunophenotype analysis involves use of antibodies to identify cell antigens (many termed clusters of differentiation or CD, see Appendix I) which correlate with lineage and maturity (Table 22.2). Other antigens, e.g. TdT, and cytoplasmic immunoglobulin may be also be detected.</li>
                            <li>Cytogenetic analysis gives diagnostic and prognostic information (Tables 22.3 and 22.4).</li>
                        </ul>

                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 22.1 French-American-British (FAB) classification of acute leukaemia.*</caption>
                                <thead>
                                    <tr>
                                        <th colspan="2">Myeloid</th>
                                        <th>Lymphoid</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>M0</td>
                                        <td>Undifferentiated by morphology + cytochemistry, myeloid immunophenotype</td>
                                        <td>L1 Small cells, high nuclear/cytoplasmic ratio</td>
                                    </tr>
                                    <tr>
                                        <td>M1</td>
                                        <td>Little differentiation, &gt;90% blasts</td>
                                        <td>L2 Larger cells, lower nuclear/cytoplasmic ratio</td>
                                    </tr>
                                    <tr>
                                        <td>M2</td>
                                        <td>Differentiated, 30-90% blasts</td>
                                        <td>L3 Vacuolated, basophilic blast cells</td>
                                    </tr>
                                    <tr>
                                        <td>M3</td>
                                        <td>Promyelocytic: intensely granular, variant form is microgranular</td>
                                        <td rowspan="5"></td>
                                    </tr>
                                    <tr>
                                        <td>M4</td>
                                        <td>Myelomonocytic</td>
                                    </tr>
                                    <tr>
                                        <td>M5a</td>
                                        <td>Monocytic with differentiation</td>
                                    </tr>
                                    <tr>
                                        <td>M5b</td>
                                        <td>Monocytic without differentiation</td>
                                    </tr>
                                    <tr>
                                        <td>M6</td>
                                        <td>Erythroid differentiation, &gt;50% of mononuclear cells are erythroid</td>
                                    </tr>
                                    <tr>
                                        <td>M7</td>
                                        <td>Megakaryoblastic</td>
                                        <td></td>
                                    </tr>
                                </tbody>
                                <tfoot>
                                    <tr>
                                        <td colspan="3" style="font-size: 0.9em; padding-top: 1em;">* All subtypes have &gt;30% blast cells in the bone marrow.</td>
                                    </tr>
                                </tfoot>
                            </table>
                        </div>

                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 22.2 Immunophenotypes of acute leukaemia.</caption>
                                <tbody>
                                    <tr>
                                        <td><strong>AML</strong></td>
                                        <td>CD33, CD13</td>
                                    </tr>
                                    <tr>
                                        <td></td>
                                        <td>Monocytic cells: CD14, CD61</td>
                                    </tr>
                                    <tr>
                                        <td></td>
                                        <td>Megakaryoblasts: CD41, CD61</td>
                                    </tr>
                                    <tr>
                                        <td></td>
                                        <td>Erythroid: glycophorin, transferrin receptor (CD71)</td>
                                    </tr>
                                    <tr>
                                        <td colspan="2"><strong>ALL</strong></td>
                                    </tr>
                                    <tr>
                                        <td>Early B-precursors (Pro-B)</td>
                                        <td>CD19,TdT</td>
                                    </tr>
                                    <tr>
                                        <td>Common ALL</td>
                                        <td>CD10, CD19, cyt CD22, TdT</td>
                                    </tr>
                                    <tr>
                                        <td>Pre B-ALL</td>
                                        <td>cyIg, CD19, cyt CD22, TdT</td>
                                    </tr>
                                    <tr>
                                        <td>B-ALL</td>
                                        <td>sMIg, CD19, CD20</td>
                                    </tr>
                                    <tr>
                                        <td>T-ALL</td>
                                        <td>CD7, cyt CD3,TdT</td>
                                    </tr>
                                </tbody>
                                <tfoot>
                                    <tr>
                                        <td colspan="2" style="font-size: 0.9em; padding-top: 1em;">CD34 is a marker of haemopoietic stem cells and may be positive in both AML and ALL. ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; B-ALL, B cell ALL; CyIg, cytoplasmic immunoglobin; sMIg, surface membrane immunoglobulin; T-ALL, T cell ALL; TdT, terminal deoxynucleotidyl transferase.</td>
                                    </tr>
                                </tfoot>
                            </table>
                        </div>

                        <div class="table-container">
                             <table class="content-table">
                                 <caption>Table 22.3 Cytogenetic changes in acute myeloid leukaemia.</caption>
                                 <tbody>
                                     <tr>
                                         <td><strong>Good risk</strong></td>
                                         <td>M2:t(8,21)<br>M3:t(15,17)<br>M4 eosinophilia: inversion 16</td>
                                     </tr>
                                     <tr>
                                         <td><strong>Poor risk</strong></td>
                                         <td>Monosomy 5, monosomy 7<br>Complex karyotypes<br>11q 23 abnormalities</td>
                                     </tr>
                                     <tr>
                                         <td><strong>Standard risk</strong></td>
                                         <td>All other cases</td>
                                     </tr>
                                 </tbody>
                             </table>
                        </div>
                        
                        <div class="image-grid">
                            <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-060-1.jpg" alt="Bone marrow slide showing T-cell acute lymphoblastic leukaemia (T-ALL) with numerous lymphoblasts having a high nuclear-to-cytoplasmic ratio." class="content-image">
                                <figcaption>Fig. 22.1 T-cell acute lymphoblastic leukaemia (T-ALL): bone marrow</figcaption>
                            </figure>
                            <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-060-2.jpg" alt="Bone marrow slide of B-cell ALL showing large blasts with vacuoles and blue cytoplasm." class="content-image">
                                <figcaption>Fig.22.2 B-cell ALL: bone marrow</figcaption>
                            </figure>
                            <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-060-3.jpg" alt="Bone marrow slide of Common ALL with periodic acid-Schiff stain, showing block positivity in blast cells." class="content-image">
                                <figcaption>Fig. 22.3 Common ALL: bone marrow-periodic acid-Schiff stain</figcaption>
                            </figure>
                            <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-060-4.jpg" alt="Cerebrospinal fluid cytocentrifuge specimen from a patient with Common ALL, showing the presence of lymphoblasts." class="content-image">
                                <figcaption>Fig. 22.4 Common ALL: cerebrospinal fluid</figcaption>
                            </figure>
                            <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-061-1.jpg" alt="Bone marrow slide of AML M0." class="content-image">
                                <figcaption>Fig. 22.5 Acute myeloid leukaemia: bone marrow-M0.</figcaption>
                            </figure>
                            <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-061-2.jpg" alt="Bone marrow slide of AML M1 stained with Sudan black, showing primary granules." class="content-image">
                                <figcaption>Fig.22.6 Acute myeloid leukaemia: bone marrow-M1 (Sudan black stain).</figcaption>
                            </figure>
                             <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-061-3.jpg" alt="Bone marrow slide of AML M2 showing a myeloblast with an Auer rod." class="content-image">
                                <figcaption>Fig.22.7 Acute myeloid leukaemia: bone marrow-M2. Note Auer rod in myeloblast.</figcaption>
                            </figure>
                             <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-061-4.jpg" alt="Bone marrow slide of AML M3 showing a cell with multiple Auer rods." class="content-image">
                                <figcaption>Fig. 22.8 Acute myeloid leukaemia: bone marrow-M3. Note cell with multiple Auer rods.</figcaption>
                            </figure>
                             <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-061-5.jpg" alt="Bone marrow slide of AML M4 with combined esterase stain, showing blue myeloblasts and brown monoblasts." class="content-image">
                                <figcaption>Fig. 22.9 Acute myeloid leukaemia: bone marrow-M4. Combined esterase stain.</figcaption>
                            </figure>
                             <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-061-6.jpg" alt="Bone marrow slide of AML M5 showing vacuolated monoblasts." class="content-image">
                                <figcaption>Fig.22.10 Acute myeloid leukaemia: bone marrow-M5.</figcaption>
                            </figure>
                             <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-062-1.jpg" alt="Bone marrow slide of AML M6 showing abnormal erythroid cells, erythroblasts, and myeloblasts." class="content-image">
                                <figcaption>Fig.22.11 Acute myeloid leukaemia: bone marrow-M6.</figcaption>
                            </figure>
                             <figure>
                                <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-062-2.jpg" alt="Bone marrow slide of AML M7 showing myeloblasts and megakaryoblasts, with platelets budding from the cytoplasm." class="content-image">
                                <figcaption>Fig. 22.12 Acute myeloid leukaemia: bone marrow-M7.</figcaption>
                            </figure>
                        </div>
                    </div>
                </section>

                <section id="treatment" class="content-section" aria-labelledby="section-heading-7">
                    <h2 id="section-heading-7" class="section-heading">
                        <span class="heading-text">Treatment</span>
                    </h2>
                    <div class="content-card">
                        <p>The first phase of therapy (remission-induction) is with high-dose intensive combination chemotherapy to reduce or eradicate leukaemic cells from the bone marrow and reestablish normal haemopoiesis. Further therapy is postinduction chemotherapy: this may be intensive ('intensification' or 'consolidation' chemotherapy) or less intensive (maintenance chemotherapy). Each course of intensive treatment typically requires 4-6 weeks in hospital.</p>

                        <h3 class="subsection-heading">Acute myeloid leukaemia</h3>
                        <p>Remission induction regimes usually comprise an anthracycline (e.g. daunorubicin), cytosine arabinoside and etoposide or thioguanine. All trans retinoic acid (ATRA) is given concurrently in AML M3 to induce differentiation. More than 80% of patients under the age of 60 years achieve remission, defined as a normal full blood count and film with &lt;5% blasts in bone marrow, with one course and &gt;85% with two courses. Older patients and those with preceding MDS or AML secondary to another disease (e.g. myeloproliferative disorder, MPD) have lower remission rates. Three or four further courses are given as postinduction therapy, and other agents used include mitoxantrone, M-AMSA, idarubicin and high dose ara-c.</p>

                        <h3 class="subsection-heading">Acute lymphoblastic leukaemia</h3>
                        <p>Remission induction regimes comprise vincristine, prednisolone and l-asparaginase often with daunorubicin, cyclophosphamide. Post-remission therapy is with two or three 'intensification' blocks with additional drugs. Patients then receive maintenance chemotherapy for a further 2 to 3 years with daily mercaptopurine, weekly methotrexate and monthly vincristine and prednisolone.</p>
                        <p>Central nervous system involvement is common in ALL in children and adults, and normal practice is to give multiple intrathecal injections and courses of high-dose systemic chemotherapy with methotrexate or cranial radiotherapy to prevent or treat this complication.</p>

                        <h3 class="subsection-heading">Stem cell transplantation (see Chapter 38)</h3>
                        <p>Allogeneic stem cell transplantation (SCT) is usually recommended for patients (&lt;50 years) in first remission of AML and for adults with ALL (&gt;20 years, &lt;50 years) who have a histocompatible sibling. Good prognosis AML (Table 22.3) and ALL (Table 22.4) cases are not usually given SCT in first remission. Autologous peripheral blood stem cell transplant (PBSCT) in some studies has improved cure rate compared to chemotherapy alone in AML and adult ALL in first or subsequent remission.</p>
                        <p>Complications of chemotherapy and supportive care are considered in Chapter 39; blood component therapy is considered in Chapter 37.</p>
                    </div>
                </section>

                <section id="prognosis" class="content-section" aria-labelledby="section-heading-8">
                    <h2 id="section-heading-8" class="section-heading">
                        <span class="heading-text">Prognosis</span>
                    </h2>
                    <div class="content-card">
                        <div class="table-container">
                             <table class="content-table">
                                 <caption>Table 22.4 Prognostic factors in acute lymphoblastic leukaemia.</caption>
                                 <thead>
                                     <tr>
                                         <th></th>
                                         <th>Good</th>
                                         <th>Bad</th>
                                     </tr>
                                 </thead>
                                 <tbody>
                                     <tr>
                                         <td>Sex</td>
                                         <td>Female</td>
                                         <td>Male</td>
                                     </tr>
                                     <tr>
                                         <td>Age</td>
                                         <td>2-9 years</td>
                                         <td>Adult</td>
                                     </tr>
                                     <tr>
                                         <td>White cell count</td>
                                         <td>Low (&lt;10 x 10<sup>9</sup>/L)</td>
                                         <td>High (&gt;50 x 10<sup>9</sup>/L)</td>
                                     </tr>
                                     <tr>
                                         <td>Chromosomes</td>
                                         <td>Hyperdiploid</td>
                                         <td>t(9;22), t(4;11)</td>
                                     </tr>
                                     <tr>
                                         <td>Extramedullary disease</td>
                                         <td>Absent</td>
                                         <td>Present</td>
                                     </tr>
                                     <tr>
                                         <td>Speed of remission</td>
                                         <td>4 weeks</td>
                                         <td>&gt;4 weeks</td>
                                     </tr>
                                     <tr>
                                         <td>Clearance of peripheral blood blasts</td>
                                         <td>1 week</td>
                                         <td>&gt;1 week</td>
                                     </tr>
                                     <tr>
                                         <td>Loss of minimal residual disease in bone marrow</td>
                                         <td>1-3 months</td>
                                         <td>&gt;3 months</td>
                                     </tr>
                                 </tbody>
                             </table>
                        </div>

                        <h3 class="subsection-heading">Childhood acute lymphoblastic leukaemia</h3>
                        <p>Overall 70% of children with ALL are cured, the best responses being in girls, aged 2-12 years with low presenting white cell count (&lt;10 x 10<sup>9</sup>/L) and favourable cytogenetics (Table 22.4).</p>
                        
                        <h3 class="subsection-heading">Acute myeloid leukaemia and adult acute lymphoblastic leukaemia</h3>
                        <p>Approximately 30-40% of patients are cured but this varies widely according to age and prognostic features.</p>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-21-myelodysplasia.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 55%;"></div>
                        </div>
                       <span class="progress-text">Lecture 22 of 40</span>
                    </div>
                    <a href="haematology-23-chronic-lymphocytic-leukaemia.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>